altHIGHLIGHTS

WHO Operations Supply and Logistics (OSL) continues to support COVID-19 emergency operations where global demand for critical items continues to outpace global supply availability. Since the beginning of the outbreak, OSL have shipped more than 584,000 surgical masks, 47,000 N95 masks, 620,000 gloves, 72,000 gowns and 11,000 goggles to 57 countries.

Normal 0 21 false false false FR X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Tableau Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:none; text-autospace:none; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US; mso-fareast-language:EN-US;}

SUBJECT IN FOCUS: Operations Supply and Logistics (OSL)


WHO Operations Supply and Logistics (OSL) continues to support COVID-19 emergency operations where global demand for critical items continues to outpace global supply.

WHO continues to highlight the need for prioritization of personal protective equipment (PPE) supplies for frontline healthcare workers. To help make supplies available, OSL and partners in the Pandemic Supply Chain Network (PSCN) have agreed on mechanisms to secure global warehousing for donated COVID-19 emergency supplies.

OSL are also working with ventilator and respirator equipment manufacturers to develop technical guidance for oxygen therapy and related equipment in the context of COVID-19.

Together with WFP, UNICEF and the World Bank, OSL continues to work on a proposal for a Supply Chain Coordination Cell to support the UN Crisis Management Team with improved information and coordination to support strategic guidance, operational decision-making, and overall monitoring.

Since the beginning of the outbreak, OSL have shipped more than 584,000 surgical masks, 47,000 N95 masks, 620,000 gloves, 72,000 gowns and 11,000 goggles to 57 countries.

OSL have also shipped laboratory tests to more than 120 countries to facilitate COVID-19 testing,

In cooperation with the International Humanitarian City (IHC) in Dubai and with aircraft provided by the government of the UAE, OSL organized a flight from Dubai to Iran on March 2, to support the first delivery of emergency PPE and lab tests.

In collaboration with WHO Health Operations, an Intensive Care Unit-assessment form is being finalized in order to facilitate independent assessment of ICUs and identify existing supplies to support COVID-19 response activities.

Normal 0 21 false false false FR X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Tableau Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; mso-pagination:none; text-autospace:none; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US; mso-fareast-language:EN-US;}

STRATEGIC OBJECTIVES

WHO’s strategic objectives for this response are to:

· Interrupt human-to-human transmission including reducing secondary infections among close contacts and health care workers, preventing transmission amplification events, and preventing further international spread*;

· Identify, isolate and care for patients early, including providing optimized care for infected patients;

· Identify and reduce transmission from the animal source;

· Address crucial unknowns regarding clinical severity, extent of transmission and infection, treatment options, and accelerate the development of diagnostics, therapeutics and vaccines;

· Communicate critical risk and event information to all communities and counter misinformation;

· Minimize social and economic impact through multisectoral partnerships.


*This can be achieved through a combination of public health measures, such as rapid identification, diagnosis and management of the cases, identification and follow up of the contacts, infection prevention and control in health care settings, implementation of health measures for travelers, awareness-raising in the population and risk communication.


PREPAREDNESS AND RESPONSE

To view all technical guidance documents regarding COVID-19, please go to this webpage.

WHO has developed interim guidance for laboratory diagnosis, advice on the use of masks during home care and in health care settings in the context of the novel coronavirus (2019-nCoV) outbreak, clinical management, infection prevention and control in health care settings, home care for patients with suspected novel coronavirus, risk communication and community engagement and Global Surveillance for human infection with novel coronavirus (2019-nCoV).

WHO is working closely with International Air Transport Association (IATA) and have jointly developed a guidance document to provide advice to cabin crew and airport workers, based on country queries. The guidance can be found on the IATA webpage.

WHO has been in regular and direct contact with Member States where cases have been reported. WHO is also informing other countries about the situation and providing support as requested.

WHO is working with its networks of researchers and other experts to coordinate global work on surveillance, epidemiology, mathematical modelling, diagnostics and virology, clinical care and treatment, infection prevention and control, and risk communication. WHO has issued interim guidance for countries, which are updated regularly.

WHO has prepared a disease commodity package that includes an essential list of biomedical equipment, medicines and supplies necessary to care for patients with 2019-nCoV.

WHO has provided recommendations to reduce risk of transmission from animals to humans.

WHO has published an updated advice for international traffic in relation to the outbreak of the novel coronavirus 2019-nCoV.

WHO has activated the R&D blueprint to accelerate diagnostics, vaccines, and therapeutics.

OpenWHO is an interactive, web-based, knowledge-transfer platform offering online courses to improve the response to health emergencies. COVID-19 courses can be found here. Specifically, WHO has developed online courses on the following topics: A general introduction to emerging respiratory viruses, including novel coronaviruses (available in Arabic, English, French, Chinese, Spanish, Portuguese, and Russian); Critical Care of Severe Acute Respiratory Infections (available in English and French); Health and safety briefing for respiratory diseases - ePROTECT (available in English, French, and Russian); Infection Prevention and Control for Novel Coronavirus (COVID-19) (available in English and Russian); and COVID-19 Operational Planning Guidelines and COVID-19 Partners Platform to support country preparedness and response.

WHO is providing guidance on early investigations, which are critical in an outbreak of a new virus. The data collected from the protocols can be used to refine recommendations for surveillance and case definitions, to characterize the key epidemiological transmission features of COVID-19, help understand spread, severity, spectrum of disease, impact on the community and to inform operational models for implementation of countermeasures such as case isolation, contact tracing and isolation. Several protocols are available here. One such protocol is for the investigation of early COVID-19 cases and contacts (the “First Few X (FFX) Cases and contact investigation protocol for 2019-novel coronavirus (2019-nCoV) infection”). The protocol is designed to gain an early understanding of the key clinical, epidemiological and virological characteristics of the first cases of COVID-19 infection detected in any individual country, to inform the development and updating of public health guidance to manage cases and reduce the potential spread and impact of infection.




SITUATION IN

total and new case hours

 

Globally

109 578 confirme

3809 deaths

 

China

80 904 confirme

3123 deaths (2

 

Outside of Chin

28 674 confirme

686 deaths (2

104 countries

areas (3

 

WHO RISK ASSES

 

China

NUMBERS

s in last 24

 

 

 

d (3994 new)

(225 new)

 

 

d (45 new)

3 new)

 

a

d (3949 new)

02 new)

/territories/ new)

 

SMENT

 

Very High

Normal 0 21 false false false FR X-NONE X-NONE